DRI Healthcare Trust Maintains Buy Rating From Stifel GMP as It Adds a New Drug Royalty; Price Target Kept at C$20.00
DRI Healthcare Trust Maintains Buy Rating From Stifel GMP as It Adds a New Drug Royalty; Price Target Kept at C$20.00
DRI Healthcare Trust 维持Stifel GMP的买入评级,因为它增加了新的药品特许权使用费;目标股价维持在20.00加元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册